University College Dublin

Project Sonic is currently at phase two of an investigation into the practicalities and viabilities 3D Structured hollow microneedle systems

Phase One: Market Investigation of UCD Microneedle Technology
  • Microneedle Potential Therapy Areas
  • Characterisation of UCD microneedle technology

Completed

Phase Two: – Market exploration and partnership development
  • Refine and consolidate the unmet needs in discussion with solution providers
  • External review with KOLs of the following:
    • User Requirements Specification and Functional Requirements Specification
    • Concept design
    • Technical risks and mitigation measures

Underway

Needle phobia and patient injection pain are known issues with injected drug therapies.

These issues became particularly acute during the COVID-19 vaccination programme. Microneedles address many of the shortcomings of injection systems with additional benefits including preventing needle stick injuries.

Kestrel is working on phase 2 of this UCD to identify specific clinical applications and developing routes to market with commercial partners to bring this exciting and much-needed technology to patients.

Why consider microneedles instead of traditional intradermal injections?

Needle phobia (50% of children; 25% of adolescents; 10% of general population)

  • Reduced pain due to <1.0mm needles
  • Reduced risk of needle stick injuries
  • Enables patient self-administration
  • Extends drug delivery duration
  • Manages peak drug concentration and limits saturation

Common misconceptions with regards to use of microneedles

  • Microneedles are expensive – X
  • Microneedles can only deliver a very small dose volumes – X
  • Microneedles can only be used for topical treatments – X
  • Microneedles are brittle – X
  • Microneedles cannot be manufactured in large volumes – X
  • Microneedles are only available in small arrays – X
  • Microneedles are only usable with low viscosity formulas – X

Think again!

  • Moulded hollow microneedle design reduces costs and unlocks high-volume manufacture
  • Wide choice of material options reduces risk of brittle material fragments, lowers Cost of Goods and offers flexible substrate options
  • 3D needle design injecting at different skin depths reduces drug saturation and increases intradermal drug absorption rate, increasing delivery rates
  • Large and scalable needle array (>100) enables larger injection volumes over wider area
  • Multiple parallel flow channels allow delivery of viscous, high molecular weight compounds without damaging high shear rates
  • Suitable for multiple topical and systemic drug delivery regimes